about
Waning sexual function--the most important disease-specific distress for patients with prostate cancerDistress due to unwanted side-effects of prostate cancer treatment is related to impaired well-being (quality of life)Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic studyIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Alcohol influence on acrylamide to glycidamide metabolism assessed with hemoglobin-adducts and questionnaire data.Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.Risk of suicide in men with low-risk prostate cancer.Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up studyDevelopment of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study.Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. A review.Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancerTreatment of patients with clinical T3 prostate cancer.Breast cancer associated with primary hyperparathyroidism: a nested case control study.Mortality following hip fracture in men with prostate cancer.Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.Genetic variants and family history predict prostate cancer similar to prostate-specific antigenEvidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.Epidemiology and statistical methods in prediction of patient outcome.The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.A hierarchical step-model for causation of bias-evaluating cancer treatment with epidemiological methods.Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.p53 mutations in urinary bladder cancer.Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma.Causes of death in men with localized prostate cancer: a nationwide, population-based study.Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeFine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer riskImpact of tumour size on axillary involvement and distant dissemination in breast cancer.The unrecognised cost of cancer patients' unrelieved symptoms:a nationwide follow-up of their surviving partners.Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancerRisk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients.Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics
P50
Q24679965-4011A098-CC74-49AF-B770-C56E0FCC46F4Q28218795-562AC683-FC15-4D9D-B70D-B4A039FD64ABQ29030107-9B62A7EE-E780-486C-81A6-EADE2E356744Q29417155-A335B483-FA69-4CEE-8A25-3ECDC4BED7C3Q33520759-955A4C84-1BBC-49FB-B518-FEB0025D9E26Q33719967-00C94C77-5599-499E-8DCF-4B9BF4266049Q33779753-8AE14177-8895-4074-8456-D15CDDF904ACQ33819138-ED150D54-B8B7-4040-8B7D-8A0E2B9A8C1BQ33848638-CACED764-E3EA-413A-8FA8-2F28A38DA8FBQ33913545-EC6185B1-7225-43C7-86D4-D4FCDB596017Q33965083-A14BE4D8-F4F0-4CDA-B0E8-02940F02595AQ34021773-747CD8A2-2AD8-4359-9D6A-236F2B914493Q34259095-69EC3DE6-C617-4338-B1E4-8D3EDAC3741EQ34399761-0799D5E4-917B-4DAB-9EC7-9B327A02ADA4Q34468114-D2B0B9B1-1B21-44D8-9F1D-F5A3509BF6D1Q34511194-D6EE9B7C-4A02-419E-B076-A1D018CCDD9EQ34632199-EBB0A9BA-3A9D-445C-9587-56E446D60CDEQ34769281-23424D23-6319-4AA1-BABA-00EFCABD6851Q35005045-09E36DCB-4035-4DBD-B9F2-57D4B75A5948Q35011556-A8352826-2394-46A7-8876-6AFD61302347Q35202889-7180B481-D233-4E71-AE05-CC6A0B24D0DBQ35277667-5D93E685-A02C-44A2-AE75-92FDBB7E1385Q35282592-7655B5C6-C79A-40C7-BE26-E447B37DF547Q35562724-A575183B-A2F1-4CE8-8D0A-415FCB994EBCQ35947528-7102DB10-2168-4E45-BF79-BAE02BACF67FQ36194975-461E5C4C-6AA9-4EDA-AEA6-84BB526440FEQ36194987-A683BE59-4A88-43E7-B1EB-73AAEBCDC4D9Q36477652-5907AA93-96FE-4812-8151-A389F39C964BQ36499616-4882BE40-D2B0-40A7-9EFB-91951D715731Q36602824-C5376A90-7450-4E4E-ADAD-7D1B7034B33EQ36622335-B8EB854C-2E88-4854-B436-32C7A93C923AQ36622549-AA24CBF0-D441-4EB6-AF5A-92561753F750Q36799921-387360ED-6E4C-4767-B116-06F46AB2DE45Q37061367-D4DE3176-1BB2-4F7C-B69C-5E0CA8DA7DBDQ37292847-1B5549FA-0563-46AA-B440-351472505C6FQ37345324-1C51967E-2F7F-4158-853C-CCD73255E38BQ37352758-5B32EB8F-4ED5-4125-8F01-E07792D2778EQ37394248-4401D631-C6C7-4F63-A682-FEF9D41077CBQ37604328-07640F7F-DA97-4FC0-A190-739AF0F0905AQ37632189-6B3A5BE1-608E-49C0-8D20-6BD8C733E9E7
P50
description
Zweeds onderzoeker
@nl
hulumtues
@sq
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Jan Adolfsson
@ast
Jan Adolfsson
@en
Jan Adolfsson
@es
Jan Adolfsson
@ga
Jan Adolfsson
@nl
Jan Adolfsson
@sl
Jan Adolfsson
@sq
type
label
Jan Adolfsson
@ast
Jan Adolfsson
@en
Jan Adolfsson
@es
Jan Adolfsson
@ga
Jan Adolfsson
@nl
Jan Adolfsson
@sl
Jan Adolfsson
@sq
prefLabel
Jan Adolfsson
@ast
Jan Adolfsson
@en
Jan Adolfsson
@es
Jan Adolfsson
@ga
Jan Adolfsson
@nl
Jan Adolfsson
@sl
Jan Adolfsson
@sq
P106
P21
P27
P31
P496
0000-0003-2992-1869